MetaCap

Eloxx Pharmaceuticals (ELOX) vs Instil Bio (TIL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eloxx Pharmaceuticals is the larger company by market cap ($43.7 million vs $35.5 million), about 1.2 times the size, while Instil Bio is growing revenue faster (+152.4% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELOX-2.91%TIL-34.79%
+97%+28%-41%
Jun 9, 20261 yearNov 20, 2026
ELOX-20.93%TIL-33.96%
+60%+11%-38%
Jun 8, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELOX versus TIL key metrics
MetricELOXTIL
Share price$10.69$5.23
Market cap$43.69M$35.47M
1-day change-1.75%-5.77%
YTD return—-52.45%
1-year return—-60.20%
5-year return—-98.72%
P/E ratio (TTM)5.63—
EPS (TTM)$1.90$-3.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$10.77M
Revenue growth (YoY)-100.00%+152.38%
Net income (latest FY)$-6.00M$-71.37M
Operating margin—-745.39%
Net margin—-662.75%
52-week high$23.40$12.92
52-week low$8.20$5.14
Distance from 52-week high-54.32%-59.51%
Analyst consensusnonenone
Avg. price target upside+257.81%+33.84%
Average volume28.48K42.02K
Shares outstanding4.09M6.78M
Employees1017
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Instil Bio grew revenue faster in its latest fiscal year (+152.38% vs -100.00%).

About Eloxx Pharmaceuticals

ELOX stock →

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees

About Instil Bio

TIL stock →

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees

ELOX vs TIL FAQ

Which is bigger, Eloxx Pharmaceuticals or Instil Bio?

Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $43.69M compared with $35.47M for Instil Bio (TIL).

Are Eloxx Pharmaceuticals and Instil Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons